The cholesterol content of western diets plays a major role in the paradoxical increase in high-density lipoprotein cholesterol and upregulates the macrophage reverse cholesterol transport pathway

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 11, 2011, Pages 2493-2499

  Escolà Gil, Joan Carles ^a,b   Llaverias, Gemma ^a,b   Julve, Josep ^a,b   Jauhiainen, Matti ^c   Méndez González, Jesús ^a,d   Blanco Vaca, Francisco ^a,b,d,e  

^a BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

ABCG5 G8; dietary fat; HDL; Macrophages; reverse cholesterol transport

Indexed keywords

ABCG5 PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL FREE DIET; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIET THERAPY; FECES; FEMALE; HIGH SATURATED FATTY ACID AND CHOLESTEROL CONTAINING DIET; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; LOW FAT DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; DIETARY FATS; FECES; LIPID METABOLISM; LIPOPROTEINS; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, ANIMAL; UP-REGULATION;

EID: 80054943313     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.236075     Document Type: Article

References (52)

1. Kushi LH, Lew RA, Stare FJ, Ellison CR, el Lozy M, Bourke G, Daly L, Graham I, Hickey N, Mulcahy R, et al. Diet and 20-year mortality from coronary heart disease: the Ireland-Boston Diet-Heart Study. N Engl J Med. 1985;312:811-818. (Pubitemid 15116925)
2. Lichtenstein AH, Schwab US. Relationship of dietary fat to glucose metabolism. Atherosclerosis. 2000;150:227-243. (Pubitemid 30336535)
3. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res. 1990;31:1149-1172. (Pubitemid 20224714)
4. Schaefer EJ, Levy RI, Ernst ND, Van Sant FD, Brewer HB Jr. The effects of low cholesterol, high polyunsaturated fat, and low fat diets on plasma lipid and lipoprotein cholesterol levels in normal and hypercholesterolemic subjects. Am J Clin Nutr. 1981;34:1758-1763. (Pubitemid 12245273)
5. Ehnholm C, Huttunen JK, Pietinen P, Leino U, Mutanen M, Kostiainen E, Pikkarainen J, Dougherty R, Iacono J, Puska P. Effect of diet on serum lipoproteins in a population with a high risk of coronary heart disease. N Engl J Med. 1982;307:850-855. (Pubitemid 12067892)
6. Nestel P, Tada N, Billington T, Huff M, Fidge N. Changes in very low density lipoproteins with cholesterol loading in man. Metabolism. 1982; 31:398-405. (Pubitemid 12142973)
7. Cole TG, Patsch W, Kuisk I, Gonen B, Schonfeld G. Increases in dietary cholesterol and fat raise levels of apoprotein EAcontaining lipoproteins in the plasma of man. J Clin Endocrinol Metab. 1983;56:1108-1115. (Pubitemid 13055101)
8. Zanni EE, Zannis VI, Blum CB, Herbert PN, Breslow JL. Effect of egg cholesterol and dietary fats on plasma lipids, lipoproteins, and apoproteins of normal women consuming natural diets. J Lipid Res. 1987; 28:518-527. (Pubitemid 17116186)
9. Knuiman JT, West CE, Katan MB, Hautvast JG. Total cholesterol and high density lipoprotein cholesterol levels in populations differing in fat and carbohydrate intake. Arteriosclerosis. 1987;7:612-619. (Pubitemid 18005813)
10. Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis. 2008;197:710-717. (Pubitemid 351417868)
11. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr. 2003;77:1146-1155. (Pubitemid 44858429)
12. Shepherd J, Packard CJ, Stewart JM, Vallance BD, Lawrie TD, Morgan HG. The relationship between the cholesterol content and subfraction distribution of plasma high-density lipoproteins. Clin Chim Acta. 1980; 101:57-62. (Pubitemid 10129765)
13. Brinton EA, Eisenberg S, Breslow JL. A low-fat diet decreases high density lipoprotein (HDL) cholesterol levels by decreasing HDL apolipoprotein transport rates. J Clin Invest. 1990;85:144-151. (Pubitemid 20030303)
14. VelezAcarrasco W, Lichtenstein AH, Welty FK, Li Z, Lamon-Fava S, Dolnikowski GG, Schaefer EJ. Dietary restriction of saturated fat and cholesterol decreases HDL ApoA-I secretion. Arterioscler Thromb Vasc Biol. 1999;19:918-924. (Pubitemid 29177338)
15. Blum CB, Levy RI, Eisenberg S, Hall M III, Goebel RH, Berman M. High density lipoprotein metabolism in man. J Clin Invest. 1977;60: 795-807. (Pubitemid 8208471)
16. Nestel PJ, Billington T, Smith B. Low density and high density lipoprotein kinetics and sterol balance in vegetarians. Metabolism. 1981;30: 941-945. (Pubitemid 11004859)
17. Berglund L, Oliver EH, Fontanez N, Holleran S, Matthews K, Roheim PS, Ginsberg HN, Ramakrishnan R, Lefevre M. HDL-subpopulation patterns in response to reductions in dietary total and saturated fat intakes in healthy subjects. Am J Clin Nutr. 1999;70:992-1000.
18. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50(suppl):S189-S194.
19. Sola R, Motta C, Maille M, Bargallo MT, Boisnier C, Richard JL, Jacotot B. Dietary monounsaturated fatty acids enhance cholesterol efflux from human fibroblasts. Relation to fluidity, phospholipid fatty acid composition, overall composition, and size of HDL3. Arterioscler Thromb. 1993;13:958-966. (Pubitemid 23195796)
20. Blanco-Molina A, Castro G, Martin-Escalante D, Bravo D, Lopez-Miranda J, Castro P, Lopez-Segura F, Fruchart JC, Ordovas JM, Perez-Jimenez F. Effects of different dietary cholesterol concentrations on lipoprotein plasma concentrations and on cholesterol efflux from Fu5AH cells. Am J Clin Nutr. 1998;68:1028-1033. (Pubitemid 28493962)
21. Montoya MT, Porres A, Serrano S, Fruchart JC, Mata P, Gerique JA, Castro GR. Fatty acid saturation of the diet and plasma lipid concen-trations, lipoprotein particle concentrations, and cholesterol efflux capacity. Am J Clin Nutr. 2002;75:484-491. (Pubitemid 34174941)
22. De Vries R, Beusekamp BJ, Kerstens MN, Groen AK, Van Tol A, Dullaart RP. A low-saturated-fat, lowAcholesterol diet decreases plasma CETP activity and prë-HDL formation but does not affect cellular cholesterol efflux to plasma from type 1 diabetic patients. Scand J Clin Lab Invest. 2005;65:729-737. (Pubitemid 41759169)
23. Buonacorso V, Nakandakare ER, Nunes VS, Passarelli M, Quintao EC, Lottenberg AM. Macrophage cholesterol efflux elicited by human total plasma and by HDL subfractions is not affected by different types of dietary fatty acids. Am J Clin Nutr. 2007;86:1270-1277. (Pubitemid 350126227)
24. Kralova Lesna I, Suchanek P, Kovar J, Stavek P, Poledne R. Replacement of dietary saturated FAs by PUFAs in diet and reverse cholesterol transport. J Lipid Res. 2008;49:2414-2418.
25. Escola-Gil JC, Rotllan N, Julve J, Blanco-Vaca F. In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: new tools for predicting HDL atheroprotection. Atherosclerosis. 2009;206:321-327.
26. Calpe-Berdiel L, Rotllan N, Fievet C, Roig R, Blanco-Vaca F, Escola-Gil JC. Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ABCG5/G8. J Lipid Res. 2008;49:1904-1911.
27. Julve J, Escola-Gil JC, Rotllan N, Fievet C, Vallez E, de la Torre C, Ribas V, Sloan JH, Blanco-Vaca F. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and highdensity lipoprotein proteome. Arterioscler Thromb Vasc Biol. 2010;30: 232-238.
28. Van Haperen R, Van Tol A, Vermeulen P, Jauhiainen M, Van Gent T, Van den Berg P, Ehnholm S, Grosveld F, Van der Kamp A, de Crom R. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol. 2000;20:1082-1088. (Pubitemid 30207586)
29. Rotllan N, Llaverias G, Julve J, Jauhiainen M, Calpe-Berdiel L, Hernandez C, Simo R, Blanco-Vaca F, Escola-Gil JC. Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. Biochim Biophys Acta. 2011;1811:104-110.
30. Rotllan N, Ribas V, Calpe-Berdiel L, MartinAcampos JM, Blanco-Vaca F, Escola-Gil JC. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol. 2005;25:e128-e132.
31. Escola-Gil JC, Blanco-Vaca F, Julve J. Overexpression of human apolipoprotein A-II in transgenic mice does not increase their susceptibility to insulin resistance and obesity. Diabetologia. 2002;45:600-601. (Pubitemid 34533843)
32. Rader DJ, Gregg RE, Meng MS, Schaefer JR, Zech LA, Benson MD, Brewer HB Jr. In vivo metabolism of a mutant apolipoprotein, apoAIIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J Lipid Res. 1992;33:755-763.
33. Hayek T, Ito Y, Azrolan N, Verdery RB, Aalto-Setala K, Walsh A, Breslow JL. Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL cholesterol ester and apolipoprotein (Apo) A-I: presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice. J Clin Invest. 1993;91:1665-1671. (Pubitemid 23127371)
34. Escola-Gil JC, Julve J, MarzalAcasacuberta A, Ordonez-Llanos J, Gonzalez-Sastre F, Blanco-Vaca F. ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance. J Lipid Res. 2001;42:241-248. (Pubitemid 32206836)
35. Calpe-Berdiel L, Escola-Gil JC, Rotllan N, Blanco-Vaca F. Phytosterols do not change susceptibility to obesity, insulin resistance, and diabetes induced by a high-fat diet in mice. Metabolism. 2008;57:1497-1501.
36. Kontush A, Chapman MJ. Why is HDL functionally deficient in type 2 diabetes? Curr Diab Rep. 2008;8:51-59. (Pubitemid 351384876)
37. Gillotte KL, Lund-Katz S, de la Llera-Moya M, Parks JS, Rudel LL, Rothblat GH, Phillips MC. Dietary modification of high density lipoprotein phospholipid and influence on cellular cholesterol efflux. J Lipid Res. 1998;39:2065-2075. (Pubitemid 28462364)
38. Gatto LM, Lyons MA, Brown AJ, Samman S. Trans fatty acids affect lipoprotein metabolism in rats. J Nutr. 2002;132:1242-1248. (Pubitemid 34606458)
39. Basso F, Amar MJ, Wagner EM, Vaisman B, Paigen B, Santamarina-Fojo S, Remaley AT. Enhanced ABCG1 expression increases atherosclerosis in LDLr-KO mice on a Western diet. Biochem Biophys Res Commun. 2006;351:398-404. (Pubitemid 44679753)
40. Lee-Rueckert M, Silvennoinen R, Rotllan N, Judstrom I, Blanco-Vaca F, Metso J, Jauhiainen M, Kovanen PT, Escola-Gil JC. Mast cell activation in vivo impairs the macrophage reverse cholesterol transport pathway in the mouse. Arterioscler Thromb Vasc Biol. 2011;31:520-527.
41. Nakaya K, Tohyama J, Naik SU, Tanigawa H, MacPhee C, Billheimer JT, Rader DJ. Peroxisome proliferator-activated receptor-activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway. Arterioscler Thromb Vasc Biol. 2011;31: 1276-1282.
42. Woollett LA, Kearney DM, Spady DK. Diet modification alters plasma HDL cholesterol concentrations but not the transport of HDL cholesteryl esters to the liver in the hamster. J Lipid Res. 1997;38:2289-2302. (Pubitemid 27495388)
43. Mitro N, Mak PA, Vargas L, Godio C, Hampton E, Molteni V, Kreusch A, Saez E. The nuclear receptor LXR is a glucose sensor. Nature. 2007;445:219-223. (Pubitemid 46095727)
44. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, Sundseth SS, Winegar DA, Blanchard DE, Spencer TA, Willson TM. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem. 1997;272:3137-3140. (Pubitemid 27066798)
45. Nishimoto T, Pellizzon MA, Aihara M, Stylianou IM, Billheimer JT, Rothblat G, Rader DJ. Fish oil promotes macrophage reverse cholesterol transport in mice. Arterioscler Thromb Vasc Biol. 2009;29:1502-1508.
46. Sehayek E, Hazen SL. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler Thromb Vasc Biol. 2008;28:1296-1297.
47. Lo Sasso G, Murzilli S, Salvatore L, D'Errico I, Petruzzelli M, Conca P, Jiang ZY, Calabresi L, Parini P, Moschetta A. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab. 2010;12:187-193.
48. Van der Velde AE, Vrins CL, Van den Oever K, Seemann I, Oude Elferink RP, Van Eck M, Kuipers F, Groen AK. Regulation of direct transintestinal cholesterol excretion in mice. Am J Physiol Gastrointest Liver Physiol. 2008;295:G203-G208.
49. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM. HDL and the inflammatory response induced by LDLderived oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2001;21: 481-488. (Pubitemid 32323377)
50. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116:3015-3025. (Pubitemid 44684486)
51. Treguier M, Briand F, Boubacar A, Andre A, Magot T, Nguyen P, Krempf M, Sulpice T, Ouguerram K. Diet-induced dyslipidemia impairs reverse cholesterol transport in hamsters. Eur J Clin Invest. 2011;41: 921-928.
52. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J Clin Invest. 2005;115:2870-2874. (Pubitemid 41434414)